Overview

* LifeVantage ( LFVN ) Q4 revenue rises 12.6% yr/yr, misses analyst expectations, per LSEG data

* Co repurchased 0.3 mln shares for $3.1 mln in fiscal 2025

Outlook

* Company expects fiscal 2026 revenue between $225 mln and $240 mln

* LifeVantage ( LFVN ) projects fiscal 2026 adjusted EBITDA of $23 mln to $26 mln

* Company anticipates fiscal 2026 adjusted EPS between $1.00 and $1.15

* LifeVantage ( LFVN ) expects full-year tax rate of 24% to 26%

Result Drivers

* AMERICAS GROWTH - Revenue in the Americas increased 14.1%, driven by strong growth in the United States

* INTERNATIONAL EXPANSION - Asia/Pacific & Europe revenue rose 7.6%, with growth attributed to the rollout of the MindBody System in Japan, Australia, Europe, and Thailand

* COST MANAGEMENT - Decrease in commissions and incentives expense as a percentage of revenue due to reduced incentive expenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Miss $55.11 $56.90

Revenue mln mln (2

Analysts

)

Q4 Gross $44.05

Profit mln

Q4 $41.90

Operatin mln

g

Expenses

Q4 $2.15

Operatin mln

g Income

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for LifeVantage Corp ( LFVN ) is $30.00, about 54.8% above its September 3 closing price of $13.57

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)